Sign in Subscribe
COVID-19

Johnson & Johnson's COVID-19 Vaccine Clears EU Approval for Single-Dose Shot

Strategic Insights

— 1 min read

The European Union's health watchdog has given the go-ahead to Johnson & Johnson's one-shot COVID-19 vaccine, adding a new player to the bloc's arsenal in the fight against the pandemic. The announcement comes as the EU's sluggish immunization campaign faces criticism, with the bloc's executive arm seeking to shift the blame to manufacturers. The vaccine, which has been shown to be 67% effective against symptomatic COVID-19 in trials, can be stored in a refrigerator for long periods and has simpler logistics compared to other vaccines. The EU has purchased 200 million doses, with an option for 200 million more.

Key Takeaways:

  • The European Commission granted a conditional marketing authorization for Johnson & Johnson's COVID-19 vaccine, adding the first single-dose shot to the bloc's arsenal.
  • The vaccine was found to be 67% effective against symptomatic COVID-19 in trials, with 72% efficacy in preventing infections in the U.S. portion of the studies.
  • The EU has purchased 200 million doses of the vaccine, with an option for 200 million more, and deliveries are expected to begin in the second half of April.
  • The vaccine can be stored in a refrigerator for long periods and has simpler logistics compared to other vaccines, making it a welcome addition to the EU's immunization effort.
  • The EU's vaccination program has faced criticism for its slow rollout, with the bloc's executive arm seeking to shift the blame to manufacturers.
  • The vaccine's protection is below what the vaccines from Pfizer-BioNTech and Moderna offer, but its ease of use and protection against severe disease make up for that.

Statistics:

  • 67%: The vaccine's effectiveness against symptomatic COVID-19 in trials.
  • 72%: The vaccine's efficacy in preventing infections in the U.S. portion of the studies.
  • 200 million: The number of vaccine doses purchased by the EU, with an option for 200 million more.
  • 2-4 weeks: The timeframe in which Germany is expected to endorse the vaccine.
  • 100 million+ people: The potential number of people who could be protected by the vaccine in the EU, Norway, and Iceland.

Sources:

  • European Commission
  • Johnson & Johnson
  • Bloomberg
  • Associated Press
  • European Medicines Agency
  • J&J statement
  • Paul Stoffels, J&J's chief scientific officer
  • Thomas Mertens, head of Germany's vaccine commission
  • Ursula von der Leyen, EU Commission President
  • GETTY IMAGES file photo

Read more